Omeros Corporation develops small-molecule and protein therapeutics targeting immunologic diseases. Products include Narsoplimab for TA-TMA, IgAN, and COVID-19; OMS1029 for lectin pathway disorders; OMS906 for Paroxysmal nocturnal hemoglobinuria and alternative pathway disorders; and OMS527 for addictions, compulsive disorders, and movement disorders. MASP-2 is a pro-inflammatory protein target for lectin pathway disorders. MASP-3 small-molecule inhibitors treat alternative pathway disorders. The company also develops Adoptive T-Cell, CAR T-Cell, Immunomodulators/Immunotoxins/Cancer Vaccines for various cancers.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 100.0 |